| |
SVR Improves Health / Cost Outcomes
|
| |
| |
4 HCV Cost-Effectiveness Studies Just Published; Costs for New Cancer/Cholesterol, Diabetes Drugs - New Model to Fund Healthcare - (04/01/15)
New Models for Healthcare Funding Needed - 08/06/14)
New Lower Prices for Gilead Hepatitis C Drugs Reach CTAF Threshold for High Health System Value.......http://www.natap.org/2014/HCV/021815_02.htm.......Gilead recently announced in 2015 average discount of 46% off the original list prices of these drugs. At this price, not only does Harvoni (or comparable treatment options) represent a high value in the care of individual patients, but its likely budget impact across broader patient populations will meet the threshold at which the California Technology Assessment Forum (CTAF) would identify it as a "high value" for most health care systems. The CTAF panel vote was informed by a drug pricing analysis performed by researchers at the University of California at San Francisco and ICER that suggested that a price range for Harvoni - or any other comparably effective drug regimen - of $34,000-$42,000 for an average course of therapy would serve as a benchmark for keeping health system cost increases below a threshold of 0.5%-1.0%. The ICER report notes that this threshold budget impact for a single new treatment is viewed by many payers as manageable without resorting to severe treatment delays or cuts in other services.
The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection - (05/11/15)
EASL: Healthcare Costs by Stage of Liver Disease in Chronic Hepatitis C Patients in the United States - (04/27/15)
EASL: SVR Reduces Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of Subjects Experiencing Liver Morbidity Over a Lifetime Horizon with AbbVie 3D (Abt-450/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment - (04/31/15)
EASL: Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States - (04/28/15)
EASL: Cost-Effectiveness of Treating Different Stages of Genotype 1 Hepatitis C Virus (GT1-HCV) With Viekira Pak (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin Compared to No Treatment in the United States - (04/31/15)
EASL: HEALTHCARE ECONOMICS / SVR Improves Health, Mortality / Early HCV Therapy Prefer - (05/14/15)
AASLD/2014: Direct Costs of Care for Hepatocellular Carcinoma in patients with Hepatitis C cirrhosis - (12/02/14)
AASLD/2014: Projected Health and Economic Impact of Hepatitis C on the United States Medicare System From 2010 to 2024 - (11/17/14)
AASLD/2014: Evaluation of the Health Outcomes for Ledipasvir / Sofosbuvir in Early vs. Delayed Treatment According to the Fibrosis Stage of Patients with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection: Results from a Decision-Analytic Markov Model....... "initiating earlier LDV/SOF treatment at F0-2 vs F3/4 reduced liver disease progression/sequalae by 66-82% & rests in lower lifetime costs by 14.3-15.9%" - (11/17/14)
AASLD/2014: LEDIPASVIR/SOFOSBUVIR SINGLE-TABLET REGIMEN FOR CHRONIC HEPATITS C (CHC) INFECTION: INSIGHTS FROM A WORK PRODUCTIVITY ECONOMIC MODEL - (11/17/14)...... "At baseline, the rates of presenteeism and absenteeism among GT1 CHC patients are 7.83% and 2.57%. As a result, not treating CHC patients is expected to result in $7.11 billion of lost productivity costs annually. In cirrhotic patients, productivity loss improvements resulting from treatment with LDV/SOF were expected to result in savings of $0.6 billion per year relative to no treatment."
Health Economics/Cost Effectiveness: Evaluation Of The Long-Term Health Outcomes Of Ledipasivir-Sofosbuvir (LDV/SOF) And Sofosbuvir-Based Regimens For Patients With Chronic Hepatitis C And Liver Cirrhosis Across Genotypes 1 To 4- (11/17/14)
".......LDV/SOF was explicitly tested in difficult to treat, protease inhibitor (PI) and peginterferon/ ribavirin (PR)-experienced GT1 patient populations, showing a reduction in HCV progression of 93% compared with NT[no treatment]. In Treat-Naive GT1, LDV/SOF was associated with a reduction of liver disease complications by 74% compared to SOF+PR. The SOF regimens also decreased the incidence of liver disease complications by 87%, 80%, and 67% in GT2 to GT4 respectively, compared to PR.......Table 5 provides the long term economic outcomes for HCV GT1 to 4 cirrhotic patients."
|
|
| |
| |
|
|
|
